Current pharmacological solutions for Behçet’s syndrome

Ozguler Y., Esatoglu S. N., Hatemi G.

Expert Opinion on Pharmacotherapy, cilt.24, sa.2, ss.221-231, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 24 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1080/14656566.2022.2155047
  • Dergi Adı: Expert Opinion on Pharmacotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.221-231
  • Anahtar Kelimeler: Behçet’s syndrome, biologics, immunosuppressives, management, small molecules, treatment
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Introduction: Behçet’s syndrome (BS) has a heterogeneous clinical phenotype, and its clinical manifestations may respond differently to drugs commonly used to treat BS. The type, dose, and duration of immunomodulatory, immunosuppressive, and biologic agents should be tailored individually. Areas covered: We reviewed the literature for articles on BS management that were published until June 2022 and summarized the management options in BS for each type of organ involvement. We aimed to cover all currently available pharmacological agents used in BS, as well as surgical and interventional options, focusing on recent evidence. Expert opinion: The management aims in BS are to preserve function and quality of life and to avoid damage. The choice of treatment modalities depends on the organs that are actively involved, the severity of that involvement, and prognostic factors. A treat-to-attack strategy would help improve long-term outcomes in BS.